de Stefano R, et al. - Researchers sought to determine whether increasing intervals between etanercept (ETN) administration could be effective in maintaining remission with a stable dose in a subjects suffering from psoriatic arthritis (PsA) who had achieved sustained remission with ETN 25 mg biweekly. They noted that peripheral polyarthritis pattern and exacerbation of cutaneous manifestations were the main reasons that hindered the dosing interval increase in ETN in PsA subjects in sustained clinical remission at standard doses. As per the data, 72% of subjects with PsA maintained a remission after a year of starting therapy, despite a progressive dose reduction by an increase in the dosing interval.